

Indiana University Health Ball Memorial Department of Research Open Clinical Trials.

AEGIS II PI: Bruce Graham, MD Coordinator - Erin Loomis

Phase 3 trial of infusing intravenous apolipoprotein A-1 (CSL112) to find out how effective this drug is in reducing the risk of heart related events in patients that have been diagnosed with Acute Coronary Syndrome (ACS). Open for enrollment.

ANTHEM HFrEF PI: Bruce Graham MD Coordinator - Erin Loomis

Device-Based therapy called Autonomic Regulation Therapy (ART) to treat patients with chronic heart failure. Open for enrollment.

APPRAISE-ATP PI: Bruce Graham, MD Coordinator - Sherry Adair

The purpose of this study is to determine which programming arm, antitachycardic pacing followed by defibrillation or defibrillation only, is the best option (works the best and is the safest) for this patient population. Open for enrollment.

ASTELLAS PI: Bruce Graham, MD Coordinator - Sherry Adair

A Phase 2 Proof of concept, double-blind, randomized, placebo-controlled study to evaluate the efficacy of ASP1128 (MA-0217) in patients at risk for acute kidney injury following coronary artery bypass graft (CABG) and/or valve surgery.

CONNECT HF PI: Wayne Gray, MD Coordinator – Sherry Adair

This study is a hospital-based quality improvement (QI) trial, comparing two QI processes in heart failure patients. Open for enrollment.

PRECISION HEALTH CONSENT (formally Indiana Biobank): Coordinator – Mona Geinosky

The purpose of this research study is to obtain a blood sample and personal health information located in one place (bank) to conduct research on many diseases and health conditions that affect Hoosiers. Open for enrollment.

PARADISE PI: Bruce Graham, MD Coordinator – Camie Carpenter

The purpose of this study is to test if LCZ696 (study drug) taken twice a day compared to Ramipril taken twice a day, is safe and effective in decreasing complications following an acute myocardial infarction (heart attack). Open for enrollment.

SOLOIST PI: Bruce Graham, MD Coordinator - Sherry Adair

This study is being done to evaluate if the study drug, Sotagliflozin, is safe for those patients that have been diagnosed with heart failure and type 2 diabetes. Open for enrollment.